Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.
10. Topical analgesic creams containing amitriptyline, ketamine, baclofen, clonidine for treating neuropathic pain
Transcript of 10. Topical analgesic creams containing amitriptyline, ketamine, baclofen, clonidine for treating neuropathic pain
designed in our clinic
other creams on the base of
classical (off-patent) analgesics.. novel... amitriptyline is a good analgesic..
but as a pill many feel sedated, as a zombie... so we decided to put it in a cream,
a 5% and a 10% cream and we published in a medical journal: and also the 10% amitriptyline cream was effective and
the tolerability was very good! since then we compounded also
other analgesic creams... based on baclofen (2 % and 5%),
and neurontin (10%)
and ISDN/lidocaine the idea was worthwhile!
patients had less pain and no side effects! and doctors can prescribe
their patients these cremes
if the drop us a note on
firstname.lastname@example.org we go for painFree! ketamine is a good analgesic
often forgotten, but proven efficacy
in CRPS in the skin many NMDA
receptors reside topical ketamine
10% and 20%
proved to be
effective and safe much evidence exists
for creme from db trials There is overwhelming anatomical and physiological data to support the use of peripheral NMDA antagonists in treatment of neuropathic pain as well as other pain states.
It is too soon to abandon this ‘‘ship”.
Commentary: Peripheral NMDA receptors revisited – Hope ﬂoats in: PAIN 146 (2009) 1–2